Drug intelligence / Profile preview

KEM2104

Development stage: Unknown
Lead developer: 长沙晶易医药
Modality: Small Molecules
Administration: Transdermal

Overview

KEM2104 is a small molecule drug candidate developed for transdermal administration, currently under investigation for the treatment of osteoarthritis. Its precise mechanism of action has not been disclosed or remains unknown. The product is being developed by Changsha Jingyi Pharmaceutical Technology Co., Ltd. There are no approved indications or known adverse events reported to date. Clinical development includes a Phase 1 trial in osteoarthritis and an additional study in healthy volunteers evaluating single and multiple dosing as well as bioavailability[1][3].

Beyond the preview

Go deeper on KEM2104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KEM2104.

Explore the full profile